Human monoclonal antibodies against EPHA4 and their use

US10934360B2 · kind B2 · utility

Assignees

• The Hong Kong University of Science and Technology
• The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services · US

Inventors

• Nancy Yuk-Yu Ip · Hong Kong, CN
• Kit Yu Fu · Hong Kong, CN
• Wing Yu Fu · Hong Kong, CN
• Dimiter S. Dimitrov · Frederick, US
• Tianlei Ying · Frederick, US

Key dates

• Filing date: Jul 31, 2015
• Grant date: Mar 2, 2021
• Expiry date: Jul 31, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vectors are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.